Seeing Is Believing
Currently out of the existing stock ratings of Matthew Sharpe, 27 are a HOLD (43.55%), 4 are a SELL (6.45%), 31 are a BUY (50%).
Analyst Matthew Sharpe, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 79.03% that have a potential upside of 19.44% achieved within 181 days.
Matthew Sharpe’s has documented 129 price targets and ratings displayed on 12 stocks. The coverage is on Industrials, Technology sectors.
Most recent stock forecast was given on PL, Planet Labs PBC at 12-Jun-2023.
Analyst best performing recommendations are on MAXR (MAXAR TECHNOLOGIES).
The best stock recommendation documented was for MAXR (MAXAR TECHNOLOGIES) at 12/14/2022. The price target of $42 was fulfilled within 2 days with a profit of $17.96 (74.71%) receiving and performance score of 373.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$190
$40.61 (27.18%)
$145
17 days ago
(04-Nov-2024)
6/7 (85.71%)
$7.91 (4.34%)
255
Sell
$175
$25.61 (17.14%)
$142
23 days ago
(29-Oct-2024)
9/9 (100%)
$-9.18 (-4.98%)
107
Hold
$185
$35.61 (23.84%)
$165
24 days ago
(28-Oct-2024)
15/15 (100%)
$-1 (-0.54%)
118
Buy
$206
$56.61 (37.89%)
$185
24 days ago
(28-Oct-2024)
14/15 (93.33%)
$20 (10.75%)
170
Buy
$196
$46.61 (31.20%)
$158
1 months 11 days ago
(10-Oct-2024)
3/4 (75%)
$36.91 (23.20%)
188
What Year was the first public recommendation made by Matthew Sharpe?